Warwick study - description and results

Trial-Results center
Clinical trial results database		Feedback Home

This trial is included in the following systematic reviews and meta-analyses:

DVT prophylaxis - antithrombotics - elective hip replacement

DVT prophylaxis - antithrombotics - orthopedic surgery

Network MA - antithrombotics - DVT prophylaxie xie orthopedique

DVT prophylaxis - heparin (UFH or LMWH) - orthopedic surgery

DVT prophylaxis - LMWH - orthopedic surgery

Related trials

RE-NOVATE 2, 2010 - dabigatran 220mg vs enoxaparin

ADVANCE 2 (CV185-047), 2010 - apixaban vs enoxaparin

RECORD 4, 2009 - rivaroxaban vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin

RECORD 2, 2008 - extended rivaroxaban vs enoxaparin

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin

RECORD 1, 2008 - extended rivaroxaban vs extended enoxaparin

HORIZONS-AMI (Stone), 2008 - bivalirudin vs Heparin plus GP IIb/IIIa inhibitor

ISAR-REACT 3, 2008 - bivalirudin vs UFH

DRIVE, 2008 - SR123781A vs enoxaparin

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)

Hull, 2006 - extended tinzaparin vs vitamin K antagonist

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

Deitcher, 2006 - extended enoxaparin vs warfarin

ACUITY (Stone) (bivalirudin alone), 2006 - bivalirudin vs heparin + anti Gp2b3a

STEEPLE, 2006 - enoxaparin vs UFH

FX140, Simonneau G, 2006 - vs

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin

See also:

All DVT prophylaxis clinical trials

All Network MA clinical trials

All clinical trials of LMWH

All clinical trials of enoxaparin

Warwick study, 1995

Treatments

Studied treatment	enoxaparin 4000x1 + elastic stockings
Control treatment	no treatment + elastic stockings

Patients

Patients

Elective hip

Baseline characteristics

Endpoint assessment

unilateral venography

Method and design

Randomized effectives	78 / 78 (studied vs. control)
Blinding	open
Follow-up duration	8-10 days

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

asymptomatic proximal DVT

12 / 78
14 / 78
0,86 [0,42;1,73]

Deep vein thrombosis

22 / 78
33 / 78
0,67 [0,43;1,03] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
Deep vein thrombosis	22 / 78 (28,2%)	33 / 78 (42,3%)	0,67	[0,43;1,03]
asymptomatic proximal DVT	12 / 78 (15,4%)	14 / 78 (17,9%)	0,86	[0,42;1,73]
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
Deep vein thrombosis	28,21%	42,31%	-141,0‰
asymptomatic proximal DVT	15,38%	17,95%	-25,6‰

Reference(s)

Trials register #

NA

Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ, Brookes S. Perioperative low-molecular-weight heparin. Is it effective and safe.. J Bone Joint Surg Br 1995 Sep;77:715-9
Pubmed | Hubmed | Fulltext

(c) 2004-2010 TrialResults-center - All Rights Reserved

Tweet this | notify a friend